FindTrial
Sign In

Obinutuzumab Injection [Gazyva]

DRUG4 trials

Sponsors

Heidelberg University, Institute of Hematology & Blood Diseases Hospital, China, Vitebsk Regional Clinical Cancer Centre

Conditions

Chronic Lymphocytic Leukaemia (CLL)Immune ThrombocytopeniaSmall Lymphocytic Lymphoma (SLL)Stage I Follicular Lymphoma Grade 1Stage II Follicular Lymphoma Grade 2Stage II Grade 1 Follicular LymphomaStage II Grade 2 Follicular LymphomaTreatment

Phase 1

Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
RecruitingNCT06762431
Vitebsk Regional Clinical Cancer CentreChronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL)
Start: 2024-05-14End: 2026-08-31Target: 24Updated: 2026-08-13

Phase 2

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma
CompletedNCT03341520
Heidelberg UniversityStage I Follicular Lymphoma Grade 1, Stage II Follicular Lymphoma Grade 2, Stage II Grade 1 Follicular Lymphoma +1
Start: 2018-04-24End: 2024-03-14Updated: 2026-04-17
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
RecruitingNCT05995054
Institute of Hematology & Blood Diseases Hospital, ChinaImmune Thrombocytopenia, Treatment
Start: 2023-08-28End: 2026-08-31Target: 110Updated: 2025-02-21
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
RecruitingNCT06094881
Institute of Hematology & Blood Diseases Hospital, ChinaImmune Thrombocytopenia, Treatment
Start: 2023-12-01End: 2026-11-30Target: 60Updated: 2025-02-24

Related Papers

Safety and preliminary efficacy of combined lenalidomide and CD19 CAR T-cell therapy in relapsed/refractory CLL: A phase I study
Blood2025-11-03
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
2019-08-3012 citations